Custom-Made vaccine takes on aggressive breast cancer

NCT ID NCT06324240

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a personalized vaccine made from a patient's own tumor, given alone or with immune-boosting drugs (pembrolizumab or ipilimumab), for triple negative breast cancer. The goal is to see if the vaccine is safe and can train the immune system to attack cancer cells. About 18 people with various stages of the disease will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
personalized tumor membrane vesicle (TMV) vaccine, pembrolizumab, ipilimumab
What this could lead to
If it works, this could lead to a new way to train the immune system to fight triple negative breast cancer and reduce the chance of it coming back.
What could go wrong
This is a very early phase I trial with only 18 participants, so it is primarily testing safety and dosing. The vaccine is personalized and complex, so results may not apply to all patients, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory Saint Joseph's Hospital

    RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact Email: •••••@•••••

    Contact

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Email: •••••@•••••

    Contact

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Email: •••••@•••••

    Contact

  • Grady Health System

    RECRUITING

    Atlanta, Georgia, 30303, United States

    Contact Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.